Trial Profile

A Phase I/II Study of Venetoclax and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lintuzumab Ac-225 (Primary) ; Venetoclax (Primary) ; Spironolactone
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Actinium Pharmaceuticals

Most Recent Events

02 Aug 2023 Planned End Date changed from 1 Jan 2023 to 1 Jun 2024.
02 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Nov 2023.
03 Apr 2023 According to an Actinium Pharmaceuticals media release, based on consequential results from this and SIERRA trial, company will initiate an Early Access Program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com